Health ❯ Healthcare ❯ Patient Care

Treatment Outcomes

Progression-Free Survival Survival Rates Adverse Effects Quality of Life Adverse Events Survivorship Neurological Conditions Blood Pressure Management Muscle Strength Improvement Clinical Response Major Molecular Response Clinical Efficacy Efficacy Metrics Complete Remission Rates Recurrence Risk Recurrence Prevention Misdiagnosis Patient Satisfaction Functional Capacity Disease-Free Survival Personalized Medicine Metastatic Cancer Response Rates

Tucatinib Added to First-Line HER2 Maintenance Prolongs Progression-Free Survival in Phase 3 Trial

Results presented at SABCS, published in JCO, show a clinically meaningful delay in progression with first-line maintenance tucatinib.

Roche’s Giredestrant Cuts Early Breast Cancer Recurrence 30% in Phase III Trial

Teclistamab–Daratumumab Delivers Major Survival Gains in Relapsed Myeloma, Phase 3 Data Show

Terns’ TERN-701 Shows Strong CML Responses in CARDINAL, Setting 320 mg and 500 mg Phase 2 Doses

Epcoritamab Added to R2 Yields Large Efficacy Gains in Relapsed Follicular Lymphoma

KOMET-007 Shows 600 mg Ziftomenib Plus Venetoclax/Azacitidine Achieves Deep Remissions in NPM1‑Mutated AML

Silevertinib Delivers 60% Response and Strong CNS Activity in First-Line NSCLC With Non-Classical EGFR Mutations

Janux Plunges on Mixed Phase 1 Prostate Cancer Data for JANX007

Final EMBARK Results Show 40% Lower Mortality With Enzalutamide Plus Leuprolide in High-Risk Recurrent Prostate Cancer

Padcev–Keytruda Cuts Recurrence and Death Risk in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

Final FLAURA2 Data Show Osimertinib Plus Chemotherapy Extends Survival in EGFR-Mutant Lung Cancer

Abivax’s Obefazimod Meets Phase 3 Week-8 Remission Goals in Ulcerative Colitis

PSMA Radioligand Before SBRT Doubles Progression-Free Survival in Oligometastatic Prostate Cancer

FDA Grants Priority Review for Enhertu Plus Pertuzumab in First-Line HER2-Positive Metastatic Breast Cancer

FDA Grants Accelerated Approval to Forzinity, First Therapy for Barth Syndrome

WCLC 2025: Combination Approaches Redraw EGFR-Mutant NSCLC Care

Triplet Therapy Doubles Survival in BRAF V600E Metastatic Colorectal Cancer